Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Waltham, Massachusetts and currently employs 43 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing drugs that improve the lives of patients with rare cardiopulmonary diseases. Its AV-101, a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. The company provides Imatinib, marketed as Gleevec tablets, is developed for the treatment of multiple cancers. Oral imatinib also demonstrates statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in pulmonary arterial hypertension (PAH) patients. PAH is an orphan disease characterized by increased pressure in the pulmonary arteries, vessels responsible for carrying deoxygenated blood from the heart to the lungs.